AB
MYGN icon

Amalgamated Bank’s Myriad Genetics MYGN Stock Holding History

Amalgamated Bank’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,838
Closed -$165K – 2375
2025
Q4 		$165K Sell
26,838
-230
-0.8% -$1.67K ﹤0.01% 1606
2025
Q3 		$196K Buy
27,068
+1,127
+4% +$6.69K ﹤0.01% 1577
2025
Q2 		$138K Hold
25,941
– – ﹤0.01% 1644
2025
Q1 		$230K Sell
25,941
-659
-2% -$7.92K ﹤0.01% 1498
2024
Q4 		$365K Sell
26,600
-56
-0.2% -$1.03K ﹤0.01% 1409
2024
Q3 		$730K Sell
26,656
-765
-3% -$20.7K 0.01% 1164
2024
Q2 		$671K Sell
27,421
-821
-3% -$18K 0.01% 1183
2024
Q1 		$602K Sell
28,242
-4,117
-13% -$88.5K 0.01% 1244
2023
Q4 		$619K Buy
32,359
+692
+2% +$12K ﹤0.01% 1352
2023
Q3 		$508K Sell
31,667
-963
-3% -$18.3K ﹤0.01% 1402
2023
Q2 		$756K Sell
32,630
-1,274
-4% -$27.8K 0.01% 1248
2023
Q1 		$788K Sell
33,904
-2,713
-7% -$55.1K 0.01% 1204
2022
Q4 		$531K Buy
36,617
+283
+0.8% +$5.27K ﹤0.01% 1438
2022
Q3 		$693K Buy
36,334
+342
+1% +$7.85K 0.01% 1263
2022
Q2 		$654K Buy
35,992
+247
+0.7% +$5.13K 0.01% 1334
2022
Q1 		$901K Sell
35,745
-1,705
-5% -$43.6K 0.01% 1248
2021
Q4 		$1.03M Buy
37,450
+214
+0.6% +$6.2K 0.01% 1212
2021
Q3 		$1.2M Sell
37,236
-613
-2% -$20.4K 0.01% 1152
2021
Q2 		$1.16M Buy
+37,849
New +$1.09M 0.01% 1214
2020
Q2 		– Sell
-11,776
Closed -$169K – 1590
2020
Q1 		$169K Sell
11,776
-254
-2% -$5.37K ﹤0.01% 1405
2019
Q4 		$328K Buy
12,030
+914
+8% +$25.1K 0.01% 1355
2019
Q3 		$318K Sell
11,116
-247
-2% -$7.2K 0.01% 1285
2019
Q2 		$316K Buy
11,363
+617
+6% +$17.4K 0.01% 1327
2019
Q1 		$357K Buy
10,746
+342
+3% +$10.4K 0.01% 1166
2018
Q4 		$302K Buy
10,404
+5,227
+101% +$188K 0.01% 1168
2018
Q3 		$238K Sell
5,177
-5,434
-51% -$242K 0.01% 1236
2018
Q2 		$397K Buy
10,611
+1,302
+14% +$44K 0.01% 1151
2018
Q1 		$275K Sell
9,309
-145
-2% -$4.91K 0.01% 1261
2017
Q4 		$325K Buy
9,454
+771
+9% +$26K 0.01% 1224
2017
Q3 		$314K Sell
8,683
-153
-2% -$4.36K 0.01% 1184
2017
Q2 		$228K Buy
+8,836
New +$188K 0.01% 1349
2016
Q2 		– Sell
-7,314
Closed -$274K – 1397
2016
Q1 		$274K Buy
7,314
+641
+10% +$24.2K 0.03% 936
2015
Q4 		$288K Sell
6,673
-603
-8% -$25.5K 0.04% 822
2015
Q3 		$273K Buy
7,276
+90
+1% +$3.19K 0.03% 941
2015
Q2 		$244K Sell
7,186
-476
-6% -$16.2K 0.02% 1127
2015
Q1 		$271K Buy
7,662
+291
+4% +$10.4K 0.03% 727
2014
Q4 		$251K Buy
7,371
+18
+0.2% +$639 0.04% 685
2014
Q3 		$284K Buy
7,353
+93
+1% +$3.47K 0.04% 619
2014
Q2 		$283K Sell
7,260
-1,202
-14% -$44.7K 0.04% 629
2014
Q1 		$289K Buy
+8,462
New +$262K 0.05% 577

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Amalgamated Bank's MYGN Position: Q1 2026 in Review

Amalgamated Bank sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 26,838 shares — an estimated $165K sold.

Amalgamated Bank first reported a position in MYGN in Q1 2014 and held it in 40 quarters. The position peaked at $1.2M in Q3 2021. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Amalgamated Bank reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 26,838 Myriad Genetics shares in Q1 2026, an estimated $165K.
  • Amalgamated Bank first reported a position in Myriad Genetics in Q1 2014 and held it in 40 quarters.
  • Amalgamated Bank's Myriad Genetics position peaked at $1.2M in Q3 2021.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.